Introduction
Mutation of the K-ras proto-oncogene is one of the most frequent and most studied events in the process of carcinogenesis. Around 30% of all cancers are associated with ras mutations, with this ®gure rising to 40 ± 50% and 90% for colorectal and pancreatic cancers respectively (Breivik et al., 1994) .
Ras proteins are molecular switches linking upstream plasma-membrane associated receptor tyrosine kinases to multiple intracellular downstream eector pathways such as the raf-MAP kinase pathway, and the phosphoinositide 3-kinase/protein kinase B (PKB/ Akt) pathway (Moodie and Wolfman 1994 , Khosravi-Far et al., 1995 , Rodriguez-Viciana et al., 1996 . Kras has been shown to aect the expression of a wide range of cancer-related genes including growth factors and genes involved in the control of cell cycle and apoptosis (Reihsaus et al., 1990) . Apoptosis represents one of the essential mechanisms by which DNAdamaged, mutant cells are eliminated from an organism. The suppression of cellular apoptotic mechanisms therefore provides a means for mutant cells to survive, accumulate further mutations and eventually generate neoplasia. The role of ras in the modulation of apoptosis is not clearly understood with some studies reporting that mutant ras inhibits apoptosis (Wolfman and Wolfman 2000 , Peli et al., 1999 , Trent et al., 1996 , Arends et al., 1993 . However, other studies have indicated that ras induces apoptosis (Navarro et al., 1999 , Chang et al., 1999 , MacKenzie et al., 1999 .
The mechanism of action by which K-ras protects a cell from apoptosis is thought to involve the downstream ras eector PI3 kinase which in turn activates PKB/Akt (Khwaja et al., 1997) . The activation of this pathway leads to the phosphorylation of both caspases and Bad which prevents complexing with Bcl-2 allowing formation of Bcl-2 homodimers that suppress induction of apoptosis (del Peso et al., 1997 , Datta et al., 1997 . Akt-kinases can also phosphorylate members of the forkhead family of transcription factors, thus suppressing apoptosis via the NF-kB pathway (Kops et al., 1999) . Other studies have indicated that in certain circumstances mutant K-ras can have the opposite eect and promote apoptosis. For example, studies have shown that ras can enhance apoptosis following cellular stress such as during loss of matrix adhesion, TNF treatment and tamoxifen treatment (McGill et al., 1997 , Trent et al., 1996 , Vater et al., 1996 . K-ras has also been shown to have a pro-apoptotic eect in Rat-1 cells during induced c-myc expression in combination with serum starvation via the raf-MAP kinase pathway (Kaumann-Zeh et al., 1997).
It is likely that the pleiotrophic nature of ras signalling results in both pro-and anti-apoptotic signals within the cell. The net result of such signalling is likely to be highly dependent on cell type and the balance of pro-and anti-apoptotic signals produced by the raf and PI3K pathways. Synergism with other cancer-related genes such as c-myc may also determine the net eect of ras mutation on apoptosis. For example, ras transforms immortalized cell lines, but not primary cultures unless they are p53 de®cient (Serrano et al., 1997) . Expression of mutant H-ras in primary ®broblasts has been shown to lead to accumulation of p53 and a state of permanent cell cycle arrest and this accumulation may be mediated by p19 ARF , one of the two tumour suppressor genes coded by the INK4a-ARF locus (Serrano et al., 1997 , Quelle et al., 1995 . In response to oncogenic stress, p53 is activated by p19 ARF through neutralization of MDM2 and as a result becomes fully active as a transcriptional activator (Levine, 1997 , Serrano et al., 1997 , Pomerantz et al., 1998 , Zhang et al., 1998 ARF is the mouse homologue of human p14 ARF , a product of the INK4a locus, which is second only to p53 in terms of mutation frequency in cancer (Haber, 1997) . Loss of this locus would presumably prevent pro-apoptotic ras signals being fed into the p53 pathway and may represent a fundamental mechanism by which ras signalling in¯uences apoptosis.
In this study, we set out to investigate the eect of mutant K-ras on the rate of apoptosis in vitro following DNA damage. To avoid the complications of aberrant cancer-related genetic changes associated with cell lines and also the expression of endogenous K-ras, we developed K-ras-null murine embryonic stem (ES) cells for use in these studies, which were transfected with K-ras expressing plasmids. These cells do not harbour mutations to genes such as c-myc or p53, which could directly in¯uence the outcome of the eect of mutant ras on apoptosis. This enabled us to recreate the stage of carcinogenesis where either both K-ras alleles are mutated, or there is one mutated and one deleted K-ras allele, rather than mutation of one allele in combination with a normal allele seen in some colorectal lesions (Breivik et al., 1994) . Furthermore, the absence of endogenous K-ras avoids any possible complicating interaction between native K-ras protein and plasmid-derived mutant K-ras protein. The K-ras null ES cells themselves also provide a useful converse system to contrast to mutant K-ras expressing cells. We also investigated expression of p19 ARF as a potential mechanism for the induction of apoptosis by oncogenic K-ras signals.
Results

Derivation of K-ras null ES cells
Heterozygous K-ras-null ES cells (K-ras +/7 ) were derived from wild-type E14 ES cells by targeting with plasmid pPTKiNKiD1 ± 3 to delete K-ras exons 1 ± 3 and confer neomycin resistance. This targeting event is shown in Figure 1a . Following neomycin (G418) selection, clones heterozygous for the targeted allele were identi®ed by Southern blotting. Figure 1b shows wild-type cells bearing the 12 kb wild-type allele (lanes 1, 2) and targeted cells heterozygous for the 7 kb allele (lanes 3, 4). Homozygous K-ras-null ES cells were derived from heterozygous cells by high-G418 selection and these cells possess only the 7 kb targeted allele (Figure 1b, lanes 5, 6) . The number of chromosomes present in these cell lines was counted and found to be 40, the normal chromosome complement for murine cells.
Derivation of reconstructed wild-type and mutant K-ras expressing cell lines
The expression of K-ras was reconstructed in homozygous K-ras 7/7 cells by the stable transfection of plasmids expressing derivatives of the K-ras minigene (Capon et al., 1983) , which contain exons 1, 2, 3, 4a and 4b, together with introns 4a and 4b (Figure 2a ). Kras reconstructed ES cells expressing glycine at codon 12 (wild-type con®guration) are hereafter referred to as K-ras gly12 ES cells and K-ras reconstructed ES cell expressing valine at codon 12 as K-ras val12 ES cells. Expression of K-ras was veri®ed at the mRNA level by semi-quantitative RT ± PCR, and expressed relative to wild-type ES cells. Expression of K-ras val12 and Kras gly12 were found to be 1.2 and 1.6 times that of wildtype K-ras expression respectively (Figure 2b ).
Induction of apoptosis in response to DNA damage by etoposide and cisplatin is enhanced by oncogenic K-ras Etoposide treatment of these cell lines resulted in a dose dependent increase in apoptosis in all cases (Figure 3) . However, the rate of apoptosis at a given concentration of etoposide varied according to the Kras status of the cells. K-ras val12 ES cells had a rate of apoptosis greater than the other cell lines in the presence of etoposide (P50.05 at all doses, Student's t-test). K-ras gly12 and wild-type ES cells had similar responses to etoposide, whereas K-ras 7/7 ES cells had a lower rate of apoptosis than the other cells in the presence of etoposide (P50.05, Student's t-test at all doses). The maximal dierence between the cell lines was observed following treatment with 5 mM etoposide, K-ras val12 ES cells had a rate of apoptosis approximately fourfold higher than K-ras 7/7 ES cells, whereas K-ras gly12 and wild-type ES cells had a rate of apoptosis approximately 1.5-fold higher than K-ras 7/7 ES cells. Dierences in the rates of apoptosis between cell lines were observed on treatment with cisplatin in a dose-dependent manner, although to a lesser extent than on treatment with etoposide ( Figure 4 ES cells had rates of apoptosis lower than the other cell lines in the presence of 50 mM and 100 mM cisplatin (P50.05, Student's t-test).
Induction of apoptosis in response to UV treatment is not affected by K-ras status UV irradiation of cell lines resulted in a dose dependent increase in apoptosis which seemed unaected by the K-ras status of the cells ( Figure 5 ). Student's t-tests con®rmed that there were no con- , with glycine or valine (mutant sequence) at codon 12 and driven by the CMV promoter, is shown. This arrangement allows splicing of the alternate K-ras 4a transcript where appropriate. The position of PCR primers for subsequent RT ± PCR is indicated by arrows. (b) RT ± PCR reactions in lanes labelled`a' were performed with a forward primer which discriminates for valine at codon 12 of the K-ras gene (e.g. K-ras val12 ES cells). Reactions in lanes labelled`b' were performed with a forward primer which discriminates for glycine at codon 12 (e.g. K-ras gly12 and wild-type [W/T] ES cells). RT ± PCR of b-actin was performed as an internal control. The level of K-ras mRNA expression in the cell lines is shown. This value is corrected for b-actin mRNA and expressed relative to the level of K-ras mRNA in wild-type ES cells sistent statistically signi®cant dierences between cell lines,`P' values between cell lines at dierent levels of UV irradiation were typically 40.1. K-ras status influences both apoptosis and the proportion of cells in G2/M phase after mild DNA damage but not in the absence of DNA damage
In the absence of DNA damage, K-ras status did not aect baseline rates of apoptosis. However, in combination with mild DNA damage, such as that induced by 5 mM etoposide, mutant K-ras expression signi®cantly enhanced apoptosis in comparison to wildtype ES cells whereas the absence of K-ras resulted in reduced apoptosis (Figure 6a ). Flow cytometric analysis of the G1/G0, S and G2/M phases of the cell cycle in the presence and absence of 5 mM etoposide showed that the cell cycle parameters of these lines were near uniform in the absence of DNA damage (Figure 6b ). However, exposure to 5 mM etoposide resulted in very similar reductions in the proportions of cells in G1/G0 and S phases for the four cell lines, but a signi®cant dierence in the proportions of G2/M cells. Whereas K-ras gly12 , wild-type and K-ras 7/7 ES cells all showed an increase in the proportion of G2/M phase cells with mild DNA damage indicating probable G2 arrest, K-ras val12 ES cells showed a signi®cant reduction in the proportion of G2/M cells as well as signi®cantly increased apoptosis (P50.05, Student's ttest).
Expression of oncogenic K-ras is associated with increased levels of p19 ARF mRNA
To investigate the possibility that the enhancement of apoptosis in response to DNA damage seen in the ES cell lines is mediated by p19 ARF , we studied the levels ARF mRNA in these cells. Semi-quantitative RT ± PCR was used to determine the amounts of p19 ARF cDNA relative to b-actin cDNA (Figure 7 ). K-ras val12 ES cells were found to express p19 ARF mRNA at a level approximately 2.5-fold more than wild-type or K-ras 7/7 ES cells. K-ras gly12 cells expressed p19 ARF mRNA 1.7 fold more than wild-type or K-ras 7/7 ES cells.
Discussion
In this study we set out to investigate the in¯uence of K-ras upon the induction of apoptosis following DNA damage. In contrast to many previous studies, this work focused on K-ras rather than any of the other ras family genes, which is an important distinction given the recent dierences highlighted in ras gene function. For example, the sequence divergence seen at the Ctermini of ras proteins and the resultant dierences in post-translation modi®cation (palmitation of H-and N-ras and the presence of lysine-rich sequences in Kras at the C-terminus) lead to localization to distinct microdomains in the cell membrane (Oli, 1999 , Roy et al., 1999 . These distinctions are paralleled by dierences in function seen between ras genes, such as the embryonic lethality seen in K-ras knockout mice, but not H-or N-ras knockouts and the variation in activation of the raf and P13K pathways between Hand K-ras (Johnson et al., 1997, Magee and Marshall 1999) . Most importantly, almost all of the ras gene mutations in colorectal and pancreatic tumours occur in K-ras with only a very few in N-ras and almost none in H-ras (Breivik et al., 1994) . Therefore, it may be specious to extrapolate results gained from other ras genes to K-ras. In order to avoid the complication of endogenous Kras expression and to provide a contrasting control, we used a model based on K-ras 7/7 ES cells in which exons 1 ± 3 of the native K-ras gene were deleted. These cells avoid potential interference with mutant K-ras protein function by wild-type K-ras protein, such as the dominant negative N-terminal eects seen with ras S17N (Feig 1999) . These cells have the distinct advantages of possessing an otherwise normal genetic background combined with the absence of endogenous K-ras which enabled us to precisely delineate the function of mutant K-ras in the control of apoptosis under these de®ned conditions. K-ras expression was reconstructed in these cells using plasmids encoding either wild-type sequence K-ras gly12 minigene or mutant K-ras val12 minigene. These minigenes allows expression of K-rasA or K-rasB isoforms as they contain both exons 4a and 4b, and have previously been shown to cause transformation of cells grown in culture (Capon et al., 1983) . We con®rmed that the K-ras minigene constructs were capable of transforming NIH3T3 cells (data not shown). This system allowed us to investigate a range of cellular K-ras environments from the presence of mutant K-ras to a scenario where K-ras is entirely absent. These cells were used as a model of the scenario of early carcinogenesis where K-ras mutations have already occurred and the cell is exposed to more DNA damage. We wished to determine if the presence of a K-ras mutation aected apoptosis as a means of allowing these cells to survive genotoxic damage and go on to acquire further mutations. To model DNA damage, we exposed cells to the DNA damaging agents etoposide, cisplatin and UV radiation.
Inhibitors of DNA topoisomerase II, such as etoposide, lead to the formation of stabilized and cleavable enzyme-DNA complexes, resulting in the generation of double-stranded DNA breaks, which are required for cytotoxicity and apoptotic cell death induced by etoposide (Chen and Liu, 1994) . We found that mutant K-ras enhanced the apoptotic response of ES cells to etoposide. K-ras val12 ES cells displayed a threefold higher incidence of apoptosis compared to K-ras 7/7 cells and a twofold higher incidence of apoptosis compared to wild-type ES cells or K-ras gly12 ES cells in the presence of 5 mM etoposide. This data is comparable with previous studies where the presence of transforming v-ras in NIH3T3 cells was found to potentiate apoptosis in response to etoposide (Chen et al., 1997) . Studies of tumour cell lines also found that those with ras mutations were more susceptible to apoptosis induced by etoposide (Koo et al., 1999) . Our data extend these ®ndings and show for the ®rst time that the absence of K-ras results in a resistance to etoposide-derived DNA damage.
The dierence between the cell lines in response to cisplatin was less marked than with etoposide, only the K-ras val12 ES cells exhibited consistently statistically signi®cant enhancement of apoptosis compared to the other cell lines. The rate of apoptosis seen with the wild-type ES cells in response to cisplatin was similar to previous studies with ES cells (Haraguchi et al., 2000) . K-ras gly12 ES cells (derived from the transfection of K-ras 7/7 ES cells with the glycine-12 K-ras minigene construct) were essentially reconstructed wild-type ES cells, and behaved in a very similar manner to wildtype ES cells in terms of response to DNA damage by etoposide and cisplatin. Both K-ras gly12 ES cells and Kras val12 ES cells expressed similar levels of K-ras mRNA compared to wild-type ES cells (1.66wild-type and 1.26wild-type respectively) indicating that dierences in cell behaviour were due to the presence of the valine mutation at codon 12 in the K-ras val12 ES cells rather than signi®cantly increased levels of K-ras expression.
The results of this study with K-ras bear interesting comparison with a recent study in which N-ras 7/7 immortalized mouse embryonic ®broblasts (MEFs) were found to be more sensitive to TNFa induced apoptosis than wild-type MEFs (Wolfman and Wolfman, 2000) . However, N-ras null MEFs were found to express higher levels of K-ras than wild-type MEFs, which in the light of our study could explain the higher incidence of apoptosis seen in these cells. In that study it was also found that K-ras knockout MEFs were less sensitive to the induction of apoptosis by TNFa compared to wild-type MEFs, which shows some parallels with the desensitization to etoposide and cisplatin-induced apoptosis seen in the K-ras 7/7 ES cells of our study.
Treatment of cells with UV radiation did not result in a statistically signi®cant dierence in apoptotic response between the cell lines. The response of the ES cells to UV irradiation in this study is comparable with that of previous work with wild-type ES cells (Corbet et al., 1999 , Haraguchi et al., 2000 . UV radiation has been shown to activate fas directly in a human keratinocyte cell line (Aragane et al., 1998) . If ES cells respond to UV in a similar fashion, this circumvention of the upstream apoptotic machinery (including K-ras and p53) may explain the uniform response to UV regardless of K-ras status.
In this study, we found that K-ras status alone does not aect intrinsic or baseline levels of apoptosis in the absence of DNA damage. K-ras val12 , K-ras gly12 ES cells and K-ras 7/7 ES cells had the same baseline levels of apoptosis as wild-type ES cells. This result emphasizes the potential problems associated with studies where ras is introduced ectopically into cell lines and the eect on apoptosis observed without comparison to the converse scenario of a K-ras null background as in this study. We observed a K-ras speci®c divergence in apoptotic response only in combination with DNA damage induced by etoposide and cisplatin.
Analysis of cell cycle parameters revealed no dierences due to K-ras status except in one important condition: the combination of even mild DNA damage and oncogenic K-ras signal (in K-ras val12 ES cells) led to enhanced apoptosis and reduced G2 arrest. In contrast, ES cells lacking oncogenic K-ras tended to respond to DNA damage by entering G2 arrest observed as an accumulation of cells in the G2/M phases of the cell cycle. These results are at variance with a previous study in NIH3T3 ®broblasts in which expression of Kras prolonged G1, reduced G2 and resulted in an inhibition of apoptosis in response to serum starvation (Orecchia et al., 2000) . Other studies have shown H-ras transformed NIH3T3 cells to undergo S phase arrest compared to non-transformed 3T3 cells which arrest in G2/M on exposure to etoposide (Chen et al., 1997) . We hypothesize that in ES cells, the combination of DNA damage together with oncogenic K-ras (as the only tumour-related gene mutation) shifts the balance of cellular signals in favour of apoptosis rather than G2 arrest as observed in wild-type, K-ras 7/7 or K-ras gly12 ES cells. The response to DNA damage in ES cells is thought to involve p53 as DNA damaging agents such as girradiation have been shown to elicit apoptosis mediated by p53 in undierentiated ES cells (Sabapathy et al., 1997 , Corbet et al., 1999 . p19 ARF has previously been shown to act as an intermediary between ras and p53 via neutralization of MDM2 . Therefore, we investigated the expression of p19 ARF expression as a potential mechanism for the enhancement of apoptosis observed in Kras val12 ES cells. K-ras gly12 ES cells expressed 1.7 times the level of p19 ARF mRNA seen in wild-type ES cells, which could be attributable to the relative level of Kras mRNA expression (K-ras gly12 ES cells expressed 1.6 times the level of K-ras mRNA seen in wild-type ES cells as measured by RT ± PCR). However, we observed a 2.5-fold increase in expression of p19 ARF mRNA in ES cells expressing mutant K-ras, which is a somewhat lower induction than that seen by others with mutant H-ras in MEFs, where a 5 ± 10-fold increase was seen, resulting in cellular senescence . The activation of p53 by oncogenic ras via p19
ARF is thought to be through a separate pathway to p53 activation from DNA damage (Kamijo et al., 1997 , Stott et al., 1998 . The results of our study showed no K-ras speci®c dierence in intrinsic apoptosis in the absence of DNA damage. However, it may be that the induction of p19 ARF by K-ras that we observed potentiates the activation of p53 leading to apoptosis when even mild DNA damage occurs. There is also evidence of other pathways linking ras to p53, such as the acetylation of p53 at lysine 382 by the tumour suppressor PML, which is itself upregulated by ras (Pearson et al., 2000) .
In conclusion, K-ras null ES cells manipulated to express K-ras val12 at near normal levels show no change in the baseline frequency of apoptosis but do show an enhanced apoptotic response to DNA-damage induced by etoposide and cisplatin, rather than the G2 arrest seen after mild DNA damage in wild-type, K-ras gly12 and K-ras 7/7 ES cells. The eects of K-ras on apoptosis appear to be mediated, at least in part by p19 ARF and have been established in conditions closely matching those of early carcinogenesis. That is, an ES cell model system with no other known tumour-related mutations as seen in immortalized or cancer cell lines, with no interference from native K-ras and using a Kras minigene construct capable of expressing K-rasA and K-rasB isoforms.
Materials and methods
Cell culture conditions and drug treatments ES cells and derivatives were maintained as monolayer cultures in gelatin-treated¯asks at 378C in a 5% CO 2 /95% air incubator in GMEM supplemented with 1 mM nonessential amino acids, 2 mM glutamine, 1 mM sodium pyruvate, 5% foetal calf serum, 5% newborn calf serum, 0.1 mM 2-mercaptoethanol and 1% recombinant leukemia inhibitory factor (LIF) produced as conditioned media from Chinese Hamster Ovary cells expressing LIF from a transiently transfected plasmid (used at a concentration double that which gave homogenous ES cell morphology).
Derivation of K-ras null ES cells
Heterozygous K-ras deleted murine ES cells were derived from E14 ES cells by transfection with pPTKiNKiD1 ± 3 a plasmid derived from pSP72 (Promega) containing regions of homology to K-ras exons 0 and 4a which¯ank a neo cassette. Heterozygous clones were selected with 100 mg ml 71 G418 (neomycin). K-ras null (K-ras 7/7 ) were derived by high-G418 selection of the heterozygous K-ras deleted cells at a concentration of 2 mg ml 71 .
Construction of expression vectors
K-ras minigenes (wild-type and valine mutant) comprising exons 1 ± 4b together with introns 4a and 4b were removed from plasmid structure II constructs (Capon et al., 1983) . The K-ras minigenes were then cloned into the mammalian expression vector PCINeo (Promega).
Construction of K-ras expressing cell lines
Wild-type and valine-mutant K-ras minigene plasmids were co-transfected with pPUR, (a puromycin-resistance expressing plasmid gifted from S Lyons, Dept Pathology, Edinburgh) at a molar ratio of 10 : 1 respectively into Kras 7/7 ES cells. The transfected cells were cultured for 14 days in the presence of 1 mg ml 71 puromycin (Sigma) after which time puromycin-resistant clones were picked. Ten independently generated cell lines were analysed in the course of this study to ensure that dierences between K-ras expressing cell lines was not simply a product of clonal variance.
Treatment of cells with DNA damaging agents
Etoposide Etoposide was dissolved in DMSO to a stock concentration of 100 mM before diluting into growth medium at the indicated concentrations.
Cisplatin Cisplatin was made up fresh, to a stock concentration of 5 mM before diluting into growth medium at the indicated concentrations. Cisplatin-containing media was left in contact with cells for 1 h before replacement with fresh growth media.
UV radiation Cells were irradiated at 254 nm using a Stratalinker 2400 (Stratagene). This device had previously been calibrated with a ®ltered photodiode UV detector so that the UV dose (expressed as Jm 72 s 71 ) with dierent attenuators (semi-transparent polyethylene sheets stretched over a frame) was known. The use of these attenuators allowed longer and therefore more accurately measurable exposure times to achieve a given dose of UV. Prior to irradiation, the media and lids were removed from the culture dishes.
Measurement of apoptosis
(i) Cells were harvested and stained with propidium iodide (Vindelov et al., 1983) . Analysis was performed on a Coulter EPICS-XL¯ow cytometer and the proportion of apoptotic cells taken as the proportion of DNA in the sub-G1/G0 (or hypodiploid) peak. (ii) To con®rm the data from¯ow cytometry, cells were harvested and stained with acridine orange. The proportions of apoptotic cells were counted by observation of nuclear morphological changes characteristic of apoptosis using¯orescent microscopy, identifying chromatin condensation and nuclear fragmentation (Arends and Wyllie, 1991) . These data correlated strongly with hypodiploid peak data from¯ow cytometric analysis.
Measurement of K-ras and p19 mRNA levels RNA was isolated from cell lines using TRIzol (Gibco) according to the manufacturer's instructions and used to synthesise cDNA using standard techniques. PCR ampli®ca-tion of K-ras cDNA was performed using a discriminating forward primer in exon 1 (5'-ACTTGTGGTAGTTGGAGC-TGG-3', for wild-type sequence and 5'-ACTTGTGGTAGT-TGGAGCTGT-3', for valine mutant sequence), together with a common reverse primer in exon 4b (5'-CACTTGTAC-TAGTATGCCTTAAG-3'). PCR conditions were 928C for 30 s, 608C for 308c and 728C for 30 s for 30 cycles.
PCR ampli®cation of murine p19 ARF cDNA transcripts was performed as previously described (Quelle et al., 1995) . Coampli®cation of b-actin cDNA was performed in parallel as an internal control, using commercially available PCR primers (Promega). PCR products were electrophoresed on 1.5% agarose gels and quantitated using Gel Doc 1000 equipment and Molecular Analyst software (BioRad).
